Table 1 Summary of recent nano-based drug delivery clinical trials for colorectal cancer
From: Recent advances in targeted drug delivery systems for resistant colorectal cancer
Type of NP | Phase | Region | Clinical Trial NO |
|---|---|---|---|
Bevacizumab and temsirolimus plus liposomal doxorubicin | I | United States | NCT00761644 |
Magnetic particle-ICG | II | United States | NCT05092750 |
Nano carbon and ICG | III | China | NCT04759820 |
TKM 080301 (lipid nanoparticles containing siRNA against the PLK1 gene product) | I | United States | NCT01437007 |
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib | II | United States | NCT03337087 |
NPs with camptothecin + CAP + RT | I/II | United States | NCT02010567 |
Liposomal SN-38 | II | United States | NCT00311610 |
Liposomal floxuridine and irinotecan HCl | II | United states | NCT00361842 |
Liposomal PEP02 or Irinotecan in Combination With Leucovorin and 5-Fluorouracil | II | France | NCT01375816 |
Thermodox (Temperature-sensitive liposomes for DOX) | II | United States | NCT01464593 |
MM-398 (Liposomal irinotecan) | I | France | NCT02640365 |
Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) | I/II | United States | NCT03368963 |
Liposomal aroplatin | II | United States | NCT00043199 |
PEGylated camptothecin formulation | II | United States | NCT00931840 |
PEGylated recombinant human granulocyte colony stimulating factor | IV | Not provided | NCT02805166 |
Arginine deiminase PEGylated plus FOLFOX | I/II | United States | NCT02102022 |
NKTR-102/ IRI (pegylated irinotecan) | II | United States | NCT00856375 |
Combination of polyclonal antibody, nanoliposomal Irinotecan, 5-FU, and leucovorin | I/II | Not provided | NCT02785068 |
Silica NPs(Fluorescent cRGDY-PEG-Cy5.5-C dots) | I/II | United States | NCT02106598 |
Polymeric NPs + cetuximab + somatostatin analogue | I | Egypt, Saudi Arabia | NCT03774680 |